Red cell distribution width as a novel prognostic marker in heart failure - Data from the CHARM program and the Duke Databank


Felker, GM; Allen, LA; Pocock, SJ; Shaw, LK; McMurray, JJV; Pfeffer, MA; Swedberg, K; Wang, DL; Yusuf, S; Michelson, EL; Granger, CB; (2007) Red cell distribution width as a novel prognostic marker in heart failure - Data from the CHARM program and the Duke Databank. Journal of the American College of Cardiology, 50 (1). pp. 40-47. ISSN 0735-1097 DOI: https://doi.org/10.1016/j.jacc.2007.02.067

Full text not available from this repository.

Abstract

Objectives The goal of this study was to identify potentially novel laboratory markers of risk in chronic heart failure patients. Background Although a variety of prognostic markers have been described in heart failure, a systematic assessment of routine laboratory values has not been reported. Methods All 2,679 symptomatic chronic heart failure patients from the North American CHARM (Candesartan in Heart Failure: Assessment of Reduction in Mortality and Morbidity) program had a wide range of laboratory measures performed at a core facility, enabling us to assess the relationship between routine blood tests and outcomes using a Cox proportional hazards model. We then replicated our findings in a cohort of 2,140 heart failure patients from the Duke Databank. Results Among 36 laboratory values considered in the CHARM program, higher red cell distribution width (RDW) showed the greatest association with morbidity and mortality (adjusted hazard ratio 1.17 per 1-SD increase, p < 0.001). Higher RDW was among the most powerful overall predictors, with only age and cardiomegaly showing a better independent association with outcome. This finding was replicated in the Duke Databank, in which higher RDW was strongly associated with all-cause mortality (adjusted hazard ratio 1.29 per 1 SD, p < 0.001), second only to age as a predictor of outcome. Conclusions In 2 large contemporary heart failure populations, RDW was found to be a very strong independent predictor of morbidity and mortality. Understanding how and why this marker is associated with outcome may provide novel insights into heart failure pathophysiology.

Item Type: Article
Keywords: Aged, Benzimidazoles, therapeutic use, Biological Markers, blood, Cause of Death, Cohort Studies, Databases as Topic, Disease Progression, Erythrocytes, cytology, Female, Heart Failure, diagnosis, drug therapy, mortality, Humans, Male, Middle Aged, Multivariate Analysis, Probability, Prognosis, Proportional Hazards Models, Randomized Controlled Trials as Topic, Risk Assessment, Sensitivity and Specificity, Severity of Illness Index, Survival Analysis, Tetrazoles, therapeutic use
Faculty and Department: Faculty of Epidemiology and Population Health > Dept of Medical Statistics
PubMed ID: 17601544
Web of Science ID: 247750600007
URI: http://researchonline.lshtm.ac.uk/id/eprint/8421

Statistics


Download activity - last 12 months
Downloads since deposit
0Downloads
324Hits
Accesses by country - last 12 months
Accesses by referrer - last 12 months
Impact and interest
Additional statistics for this record are available via IRStats2

Actions (login required)

Edit Item Edit Item